Augmedix (NASDAQ:AUGX – Get Free Report) and MoneyHero (NASDAQ:MNY – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings.
Risk & Volatility
Augmedix has a beta of -0.27, indicating that its share price is 127% less volatile than the S&P 500. Comparatively, MoneyHero has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500.
Valuation & Earnings
This table compares Augmedix and MoneyHero’s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Augmedix | $48.70 million | 2.27 | -$19.17 million | ($0.43) | -5.26 |
| MoneyHero | $80.67 million | 0.76 | -$172.60 million | ($4.72) | -0.34 |
Insider & Institutional Ownership
87.1% of Augmedix shares are held by institutional investors. Comparatively, 30.9% of MoneyHero shares are held by institutional investors. 11.0% of Augmedix shares are held by insiders. Comparatively, 19.2% of MoneyHero shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings and price targets for Augmedix and MoneyHero, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Augmedix | 0 | 4 | 0 | 0 | 2.00 |
| MoneyHero | 0 | 0 | 0 | 0 | N/A |
Augmedix presently has a consensus target price of $3.09, indicating a potential upside of 36.62%. Given Augmedix’s higher probable upside, equities analysts plainly believe Augmedix is more favorable than MoneyHero.
Profitability
This table compares Augmedix and MoneyHero’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Augmedix | -41.95% | -178.34% | -38.74% |
| MoneyHero | N/A | -840.37% | -107.59% |
Summary
Augmedix beats MoneyHero on 7 of the 12 factors compared between the two stocks.
About Augmedix
Augmedix, Inc. provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits. The company enables clinicians to access its applications through mobile devices, such as smartphones. It serves health systems and specialty groups. The company was founded in 2013 and is headquartered in San Francisco, California.
About MoneyHero
MoneyHero Limited operates as a personal finance company. It engages in operation of online financial comparison platforms and related services. The company offers its products under Money Hero, SingSaver, Money101, MoneyMax, CompareHero, Seedly, and Creatory brands. MoneyHero Limited operates in Singapore, Hong Kong, Taiwan, the Philippines, Malaysia, and Thailand. The company was founded in 2014 and is headquartered in Singapore.
Receive News & Ratings for Augmedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Augmedix and related companies with MarketBeat.com's FREE daily email newsletter.
